Our research group is interested in understanding how iron is regulated in the human body and how these processes are abrogated in disease, most notably cancer. By using both in-vitro and in-vivo models we have begun to dissect the importance of both systemic and luminal iron levels in gastrointestinal carcinogenesis.
The knowledge gained to date has led to several pending patents focused on the use of iron chelators as chemopreventive agents in high risk individuals. In close collaboration with both academic and industrial partners we are also assessing how iron chelators can be manipulated to provide safety, tolerability and effective delivery.
We are also now beginning to study iron metabolism in other non-gastrointestinal cancers settings most pertinently endocrine cancers, in addition to assessing the effects of iron both at the proteomic and metabolomic level.
In addition obesity is a risk factor for the development of several epithelial cancers and that iron metabolism is also deregulated in obesity. Thus we are dissecting out at the molecular and cellular level how iron deregulation can both contribute to a systemic anaemia whilst at the same time predispose to cancer. This work has further branched out to developing methodologies to identify other novel adipocyte secreted factors and how these impact on carcinogenesis.
Dr Chris Tselepis (group lead), Senior Lecturer
Dr Tariq Iqbal
Mr Samuel Ford
Dr Elisabeth Shawcross
Dr Imogen Williams, Clinical Lecturer in Gastroenterology
Prof Christopher McCabe
Prof Jeremy Tomlinson, MRC Senior Clinical Fellow and Reader in Endocrinology Professor Dion Morton, Professor of Surgery
Prof Derek Alderson
Ms Olga Tucker
Prof Ulrich Gunther
Dr Douglas Ward
Prof Mark Viant (Biosciences), Professor of Metabolomics
Prof Ian Norton (Chem Eng), Professor of Chemical Engineering
Zoe Pikramenou (Chem), Reader in Supramolecular Photochemistry